In addition, while Guisier et al. demonstrated no decrease in immunotherapy response in ERBB2 mutated NSCLC in a small cohort of patients, larger clinical studies need to be performed to further evaluate the role of ERBB2 mutations in immunotherapy response [19]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.